Prevalence of human papilloma virus infection in women in rural Ethiopia

European Journal of Epidemiology

Volumn 21, Issue 9, 2006, Pages 727-729

  Ruland, R ^a   Prugger, C ^a,b   Schiffer, R ^c   Regidor, M ^a   Lelle R J ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c Attat Hospital   (Ethiopia)

Author keywords

Ethiopia; HPV testing; Human papilloma virus

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTODIAGNOSIS; DISEASE ASSOCIATION; DNA DETERMINATION; ETHIOPIA; FEMALE; HUMAN; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; OUTPATIENT; RURAL AREA; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS;

ETHIOPIA; FEMALE; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 33750902015     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-006-9055-4     Document Type: Article

References (14)

1. GEKID. Krebs in Deutschland. Häufigkeiten und Trends. Saarbrücken: GEKID, Robert Koch Institut, 2006.
2. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: Concepts and clinical implications. J Pathol 2006; 208(2): 152-164.
3. Munoz N, Bosch FX, de Sanjose S . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6): 518-527.
4. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med 2005; 353(20): 2101-2104.
5. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: A pooled analysis. Lancet 2005; 366(9490): 991-998.
6. Terry G, Ho L, Londesborough P, Cuzick J, Mielzynska-Lohnas I, Lorincz A. Detection of high-risk HPV types by the hybrid capture 2 test. J Med Virol 2001; 65(1): 155-162.
7. Doll R, Payne P, Waterhouse JBS-Vf, UICC. Cancer Incidence in Five Continents: A Technical Report. Berlin: Springer Verlag, 1966.
8. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005; 353(20): 2158-2168.
9. Kelly J, Fekadu S, Lancashire RJ, Poovan P, Redito A. A follow-up of repair of ruptured uterus in Ethiopia. J Obstet Gynaecol 1998; 18(1): 50-52.
10. Denny L, Kuhn L, Pollack A, Wainwright H, Wright TC Jr. Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 2000; 89(4): 826-833.
11. El-Shalakany A, Hassan SS, Ammar E, Ibrahim MA, Salam MA, Farid M. Direct visual inspection of the cervix for the detection of premalignant lesions. J Low Genit Tract Dis 2004; 8(1): 16-20.
12. Basu PS, Sankaranarayanan R, Mandal R, et al. Visual inspection with acetic acid and cytology in the early detection of cervical neoplasia in Kolkata, India. Int J Gynecol Cancer 2003; 13(5): 626-632.
13. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 2004; 364(9447): 1757-1765.
14. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6(5): 271-278.